Development of Chitosan Nanoparticles for PRPF31 Gene Delivery in the Treatment of Retinitis Pigmentosa

INTRODUCTION: Retinitis Pigmentosa (RP), an inherited retinal disease, characterized by a progressive loss of photoreceptor cells, leading to vision impairment. Mutations in the pre-mRNA processing factor gene (PRPF31) major cause of autosomal dominant RP. While viral vectors like AAV are commonly used in gene therapy, they are limited by low DNA cargo capacity and immunogenicity. We aimed to develop a chitosan-based NPs to deliver PRPF31 plasmid DNA (pDNA) into the ARPE-19 retinal cell line. METHODS: The Complex coacervation method was used to prepare CS NPs loaded with PRPF31. The NPs were characterized for particle size, polydispersity index (PDI), and zeta potential using a zetasizer. Surface morphology of CS-based NPs was examined using SEM. Additionally, the loading capacity, encapsulation efficiency, protective effect of CS on the pDNA, in vitro transfection efficiency, and cytotoxicity were evaluated in ARPE-19 cell lines Results: The particle size, PDI, and zeta potential of chitosan nanoparticles were 245.19 ± 21.27nm, 0.265 ± 0.023, and +20.5 ± 5.63 mV, respectively. Scanning Electron Microscopy (SEM) images confirmed the formation of NPs. The pDNA encapsulation efficiency was 66.80%± 4.69 and a loading efficiency of 21.93%± 1.08. The transfection efficiency of naked pDNA in ARPE-19 cells was 24.40% while that of CS pDNA NP was 48.30%. Cells transfected with pDNA using the standard transfecting agent Lipofectamine showed a higher transfection efficiency of 65.24% as compared to both naked pDNA and CS-pDNA NPs. DISCUSSION: Cs- pDNA particles demonstrated moderate transfection efficiency and lower cytotoxicity in the retinal cell line. In vivo research is required to realize its future therapeutic potential. CONCLUSION: These CS-pDNA NPs may have potential as a non-viral delivery vehicle in gene therapy in RP, however, further research in animal models is needed to validate the in vitro findings and for their potential therapeutic applications.

Authors

Institutions

Publication Details

Journal
Current Drug Delivery
Published
2026-04-06
DOI
https://doi.org/10.2174/0115672018409641251130113502
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development of Chitosan Nanoparticles for PRPF31 Gene Delivery in the Treatment of Retinitis Pigmentosa

Erik D. Moore, Surabhi Shukla, Alekha K. Dash, Md Jobair Hossen Jony
Current Drug Delivery
RNA Interference and Gene Delivery
article

Development of Chitosan Nanoparticles for PRPF31 Gene Delivery in the Treatment of Retinitis Pigmentosa

Erik D. Moore, Surabhi Shukla, Alekha K. Dash, Md Jobair Hossen Jony
article en

Abstract

INTRODUCTION: Retinitis Pigmentosa (RP), an inherited retinal disease, characterized by a progressive loss of photoreceptor cells, leading to vision impairment. Mutations in the pre-mRNA processing factor gene (PRPF31) major cause of autosomal dominant RP. While viral vectors like AAV are commonly used in gene therapy, they are limited by low DNA cargo capacity and immunogenicity. We aimed to develop a chitosan-based NPs to deliver PRPF31 plasmid DNA (pDNA) into the ARPE-19 retinal cell line. METHODS: The Complex coacervation method was used to prepare CS NPs loaded with PRPF31. The NPs were characterized for particle size, polydispersity index (PDI), and zeta potential using a zetasizer. Surface morphology of CS-based NPs was examined using SEM. Additionally, the loading capacity, encapsulation efficiency, protective effect of CS on the pDNA, in vitro transfection efficiency, and cytotoxicity were evaluated in ARPE-19 cell lines Results: The particle size, PDI, and zeta potential of chitosan nanoparticles were 245.19 ± 21.27nm, 0.265 ± 0.023, and +20.5 ± 5.63 mV, respectively. Scanning Electron Microscopy (SEM) images confirmed the formation of NPs. The pDNA encapsulation efficiency was 66.80%± 4.69 and a loading efficiency of 21.93%± 1.08. The transfection efficiency of naked pDNA in ARPE-19 cells was 24.40% while that of CS pDNA NP was 48.30%. Cells transfected with pDNA using the standard transfecting agent Lipofectamine showed a higher transfection efficiency of 65.24% as compared to both naked pDNA and CS-pDNA NPs. DISCUSSION: Cs- pDNA particles demonstrated moderate transfection efficiency and lower cytotoxicity in the retinal cell line. In vivo research is required to realize its future therapeutic potential. CONCLUSION: These CS-pDNA NPs may have potential as a non-viral delivery vehicle in gene therapy in RP, however, further research in animal models is needed to validate the in vitro findings and for their potential therapeutic applications.

Current Drug DeliveryVol. 23
Creighton University (US)
Good health and well-being
Openalex Percentile: Top 22%
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.